Managing type 2 diabetes often becomes more difficult over time. Many people begin with lifestyle changes and metformin but later need additional medicines or even daily insulin injections. Finding treatments that provide stronger blood sugar control without adding too much complexity is an important goal for doctors and patients.
A new medicine called orforglipron may help meet that need. According to two phase 3 studies published in The Lancet and JAMA, the once-daily tablet significantly improved blood sugar control in adults with type 2 diabetes receiving different standard treatments.
Unlike most GLP-1 medicines, which are given by injection, orforglipron is taken by mouth. GLP-1 medicines work by helping the pancreas release insulin when blood sugar rises, reducing sugar production by the liver, slowing digestion, and helping control appetite. Because of these effects, they have become some of the most important medicines for diabetes treatment.
One study enrolled adults taking metformin. Participants received one of three doses of orforglipron or the diabetes medicine dapagliflozin. Over 40 weeks, people taking orforglipron achieved larger reductions in HbA1c than those receiving dapagliflozin, especially at the higher doses.
The second study focused on patients already using insulin glargine. These individuals often have more advanced diabetes and may require multiple medicines. Adding orforglipron to their treatment lowered HbA1c substantially more than adding a placebo while insulin doses were adjusted throughout the study.
Experts say this is encouraging because people using insulin frequently need additional therapies to reach recommended blood sugar targets. An effective oral GLP-1 medicine could provide another option without requiring another injection.
The researchers noted that future studies will continue to examine the medicine’s long-term effects, including its safety profile and other health benefits. If approved by regulators, orforglipron could become one of the first widely available oral non-peptide GLP-1 medicines for type 2 diabetes.
These two phase 3 clinical trials provide strong evidence that oral orforglipron can improve blood sugar control in people with type 2 diabetes, including those already taking metformin or basal insulin. The studies were large, randomized, and published in leading medical journals, making the findings credible.
However, the trials lasted only 40 weeks, so longer studies are still needed to assess long-term safety, durability of blood sugar control, weight changes, and cardiovascular outcomes. It is also important to note that Eli Lilly funded the studies, so independent research will continue to be valuable.
If you care about diabetes, please read studies about high vitamin D level linked to lower dementia risk in type 2 diabetes, and this eating habit could help reduce risk of type 2 diabetes.
For more information about nutrition, please see recent studies about unhealthy plant-based diets linked to metabolic syndrome, and results showing Mediterranean diet could help reduce the diabetes risk by 30%.
Source: American Diabetes Association / Eli Lilly.
